AstraZeneca Halts Phase 3 Volrustomig Lung Cancer Trial After Setback

The ​decision followed a recommendation from an independent data monitoring committee, which found the volrustomig combination was unlikely ​to meet either of its primary endpoints of progression-free survival or overall survival in patients whose tumours lacked the PD-L1 protein.

Separately, however, the company reported positive readouts from ​two other late-stage lung cancer trials, with its Tagrisso-Orpathys ⁠combination and ‌the Daiichi Sankyo-partnered Enhertu both meeting key goals.

Investor confidence has ​been dented ​by a series of blows, including the surprise failure of Wainua ⁠in a late-stage heart disease trial, the U.S. rejection of ​breast cancer drug camizestrant on trial design grounds, and a ​late-stage failure for rare disease drug Ultomiris.

COMPANY TARGETS 20 NEW DRUG LAUNCHES

AstraZeneca, however, stood by its forecasts in July, including its target of $80 billion in annual revenue by 2030, expressing confidence that the recent setbacks had not undermined its long-term prospects.

The drugmaker, which topped second-quarter profit expectations on strong demand for its cancer and ‌rare disease therapies, is counting on up to 20 new drug launches to help reach that target.

"While we are disappointed, we will ​learn from ​this trial," said Susan Galbraith, ⁠AstraZeneca's executive vice president for oncology haematology R&D.

The company said the safety profile of volrustomig in combination with chemotherapy was consistent with the known profiles of the individual medicines, ​with no new safety signals identified.

Other Phase III trials of volrustomig in cervical cancer, head and neck squamous cell carcinoma and mesothelioma will continue as planned.

Volrustomig is a dual checkpoint inhibitor bispecific antibody designed to unblock two key immune pathways, PD-1 and CTLA-4, to help the immune system attack tumours.